Apogee Therapeutics [APGE] vs Regeneron [REGN] Detailed Stock Comparison
Apogee Therapeutics
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Apogee Therapeutics wins in 5 metrics, Regeneron wins in 10 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Apogee Therapeutics | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -11.69 | 15.12 | Apogee Therapeutics |
| Price-to-Book Ratio | 3.62 | 2.09 | Regeneron |
| Debt-to-Equity Ratio | 1.75 | 9.04 | Apogee Therapeutics |
| PEG Ratio | -0.13 | 13.24 | Apogee Therapeutics |
| EV/EBITDA | -6.05 | 12.82 | Apogee Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.37% | Regeneron |
| Operating Margin (TTM) | 0.00% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | -34.12% | 15.34% | Regeneron |
| Return on Assets (TTM) | -23.21% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-172.33M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | -20.86% | -50.84% | Apogee Therapeutics |
| Price-to-Sales Ratio (TTM) | N/A | 4.47 | N/A |
| Enterprise Value | $1.63B | $57.26B | Regeneron |
| EV/Revenue Ratio | N/A | 4.03 | N/A |
| Gross Profit Margin (TTM) | N/A | 85.58% | N/A |
| Revenue per Share (TTM) | $0 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-4.14 | $39.66 | Regeneron |
| Beta (Stock Volatility) | 1.44 | 0.33 | Regeneron |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Apogee Therapeutics vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Apogee Therapeutics | 5.28% | 2.63% | -3.36% | -5.18% | 14.68% | -18.83% |
| Regeneron | -1.45% | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Apogee Therapeutics | -20.86% | 80.26% | 80.26% | 80.26% | 80.26% | 80.26% |
| Regeneron | -50.84% | -1.12% | -2.18% | 9.83% | 2,487.71% | 7,770.23% |
Performance & Financial Health Analysis: Apogee Therapeutics vs Regeneron
| Metric | APGE | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.28B | $63.57B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 432,804 | 900,437 |
| 90 Day Avg. Volume | 584,015 | 952,396 |
| Last Close | $38.27 | $589.48 |
| 52 Week Range | $26.20 - $63.50 | $476.49 - $1,211.20 |
| % from 52W High | -39.73% | -51.33% |
| All-Time High | $72.29 (Mar 11, 2024) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -47.06% | -51.33% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.04% |
| Quarterly Earnings Growth | N/A | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.31% |
| Operating Margin (TTM) | 0.00% | 0.30% |
| Return on Equity (TTM) | -0.34% | 0.15% |
| Debt to Equity (MRQ) | 1.75 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $10.58 | $287.55 |
| Cash per Share (MRQ) | $8.63 | $72.04 |
| Operating Cash Flow (TTM) | $-220,744,000 | $4.74B |
| Levered Free Cash Flow (TTM) | $-138,940,496 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Apogee Therapeutics vs Regeneron
| Metric | APGE | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -11.69 | 15.12 |
| Forward P/E | -10.07 | 13.24 |
| PEG Ratio | -0.13 | 13.24 |
| Price to Sales (TTM) | N/A | 4.47 |
| Price to Book (MRQ) | 3.62 | 2.09 |
| Market Capitalization | ||
| Market Capitalization | $2.28B | $63.57B |
| Enterprise Value | $1.63B | $57.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 4.03 |
| Enterprise to EBITDA | -6.05 | 12.82 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 0.33 |
| Book Value per Share (MRQ) | $10.58 | $287.55 |
Financial Statements Comparison: Apogee Therapeutics vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | APGE | REGN |
|---|---|---|
| Revenue/Sales | $0 | $3.03B |
| Cost of Goods Sold | N/A | $464.30M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $55.70M | $1.34B |
| Operating Income (EBIT) | $-73.17M | $591.70M |
| EBITDA | $-72.77M | $900.90M |
| Pre-Tax Income | $-66.02M | $905.00M |
| Income Tax | $72,000 | $96.30M |
| Net Income (Profit) | $-66.10M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | APGE | REGN |
|---|---|---|
| Cash & Equivalents | $106.92M | $3.09B |
| Total Current Assets | $521.53M | $17.57B |
| Total Current Liabilities | $32.96M | $3.57B |
| Long-Term Debt | $7.84M | $2.70B |
| Total Shareholders Equity | $673.36M | $29.39B |
| Retained Earnings | $-361.26M | $32.38B |
| Property, Plant & Equipment | $1.41M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | APGE | REGN |
|---|---|---|
| Operating Cash Flow | $-49.63M | $1.36B |
| Capital Expenditures | $-4.32M | N/A |
| Free Cash Flow | $-52.79M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | APGE | REGN |
|---|---|---|
| Shares Short | 8.40M | 2.29M |
| Short Ratio | 7.01 | 2.55 |
| Short % of Float | 0.31% | 0.02% |
| Average Daily Volume (10 Day) | 432,804 | 900,437 |
| Average Daily Volume (90 Day) | 584,015 | 952,396 |
| Shares Outstanding | 59.48M | 109.62M |
| Float Shares | 37.79M | 97.89M |
| % Held by Insiders | 0.08% | 0.02% |
| % Held by Institutions | 1.32% | 0.90% |
Dividend Analysis & Yield Comparison: Apogee Therapeutics vs Regeneron
| Metric | APGE | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |